{"id":"piperacillin-continuous-infusion","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Rash"},{"rate":"2-4","effect":"Phlebitis at infusion site"},{"rate":"1-3","effect":"Hypersensitivity reactions"},{"rate":"<1","effect":"Seizures (in renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is an extended-spectrum ureidopenicillin that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and causing cell wall lysis. When administered as a continuous infusion, it maintains sustained bactericidal concentrations at the infection site, optimizing time-dependent killing. This delivery method is particularly effective for serious infections caused by gram-negative and gram-positive bacteria.","oneSentence":"Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:25.814Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections including pneumonia, intra-abdominal infections, and sepsis"},{"name":"Hospital-acquired infections caused by susceptible gram-negative and gram-positive organisms"}]},"trialDetails":[{"nctId":"NCT07481539","phase":"PHASE2","title":"Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment","status":"RECRUITING","sponsor":"Azienda Sanitaria Universitaria Friuli Centrale","startDate":"2026-03-24","conditions":"Bacteria Infection, Piperacillin, Tazobactam Drug Combination","enrollment":240},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT02820987","phase":"PHASE3","title":"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-09-27","conditions":"Septic Shock","enrollment":119},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT05102162","phase":"PHASE4","title":"BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia","status":"TERMINATED","sponsor":"University of Florida","startDate":"2021-12-17","conditions":"Pneumonia","enrollment":35},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT04915872","phase":"","title":"Are Standard Dosing Regimens of Piperacillin-Tazobactam Suitable in Critically Ill Patients With Open Abdomen and Negative Pressure Wound Therapy? A Population Pharmacokinetic Study.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-01","conditions":"Laparotomy, Critical Illness, Piperacillin, Tazobactam Drug Combination","enrollment":46},{"nctId":"NCT04799626","phase":"","title":"Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-04-01","conditions":"Elderly Infection","enrollment":500},{"nctId":"NCT01694069","phase":"PHASE4","title":"Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT03019965","phase":"NA","title":"Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-01","conditions":"Sepsis","enrollment":426},{"nctId":"NCT04895657","phase":"PHASE4","title":"Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-07-27","conditions":"Gram-Negative Infections","enrollment":56},{"nctId":"NCT04816968","phase":"PHASE1","title":"Antibiotics Continuous Infusion at Home","status":"UNKNOWN","sponsor":"Ospedale San Carlo Borromeo","startDate":"2021-09","conditions":"Severe Bacterial Infections","enrollment":50},{"nctId":"NCT04530045","phase":"","title":"Target Attainment of TDM-guided Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2018-05-02","conditions":"Critical Illness, Antibiotic Toxicity, Sepsis","enrollment":99},{"nctId":"NCT01198925","phase":"PHASE4","title":"Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-09-23","conditions":"Infectious Disease","enrollment":14},{"nctId":"NCT01667094","phase":"PHASE4","title":"A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Alfred","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT01983787","phase":"","title":"Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-07","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT02478073","phase":"","title":"Piperacillin Pharmacokinetics in ICU Patients","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2015-06","conditions":"Sepsis, Septic Shock","enrollment":50},{"nctId":"NCT01577368","phase":"PHASE3","title":"Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2011-05","conditions":"Pseudomonas Aeruginosa Infection","enrollment":76},{"nctId":"NCT00044928","phase":"PHASE4","title":"Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-07","conditions":"Bacterial Infections","enrollment":262},{"nctId":"NCT00703144","phase":"PHASE4","title":"Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2008-06","conditions":"Diffusive and Convective Clearance, Body Clearance, Piperacillin Tazocilline Concentrations (Cmin)","enrollment":10},{"nctId":"NCT00435305","phase":"","title":"Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2006-11","conditions":"Pneumonia, Bacteremia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"piperacillin continuous infusion","genericName":"piperacillin continuous infusion","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including pneumonia, intra-abdominal infections, and sepsis, Hospital-acquired infections caused by susceptible gram-negative and gram-positive organisms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}